Suppr超能文献

乳糜泻患者的小肠腺癌、腺瘤和类癌风险:一项全国性队列研究。

Risk of Small Bowel Adenocarcinoma, Adenomas, and Carcinoids in a Nationwide Cohort of Individuals With Celiac Disease.

机构信息

Departments of General Practice and Health Management and Health Economics, Institute of Health and Society, University of Oslo, Oslo, Norway; Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden; Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Vårdcentralen Årjäng and Centre for Clinical Research, County Council of Värmland, Värmland, Sweden.

University of Chicago Medicine, Chicago, Illinois.

出版信息

Gastroenterology. 2020 Nov;159(5):1686-1694.e2. doi: 10.1053/j.gastro.2020.07.007. Epub 2020 Jul 15.

Abstract

BACKGROUND & AIMS: The incidence of small bowel cancers is increasing. Associations have been made between celiac disease (CD) and small bowel cancers, but there have been no detailed studies of large cohorts.

METHODS

Through the nationwide Epidemiology Strengthened by Histopathology Reports in Sweden cohort study, we retrieved data from Sweden's 28 pathology departments on all individuals who received a diagnosis of CD from 1965 through 2017. Individuals with CD, defined as duodenal or jejunal villous atrophy (stage 3 Marsh score), were matched with as many as 5 randomly selected reference individuals from the general population. We used stratified Cox regression to calculate hazard ratios (HRs) for small bowel adenocarcinoma, adenomas, and carcinoids.

RESULTS

During a median follow-up of 11 years, we identified 48,119 individuals with CD (patients) and 239,249 reference individuals. Beginning at 1 year after a diagnosis of CD, 29 patients (0.06%) received a diagnosis of small bowel adenocarcinoma vs 45 reference individuals (0.02%), 7 patients received a diagnosis of carcinoids vs 31 reference individuals, and 48 patients received a diagnosis of adenomas vs 50 reference individuals. Corresponding HRs were small bowel adenocarcinoma 3.05 (95% confidence interval [CI], 1.86-4.99), carcinoids 0.59 (95% CI, 0.16-2.10), and adenomas 5.73 (95% CI, 3.70-8.88). HRs were independent of sex and age. Overall, there was 1 extra case of small bowel adenocarcinoma in every 2944 patients with CD followed for 10 years. There was an inverse association between mucosal healing risk of future small bowel adenocarcinoma (HR, 0.18; 95% CI, 0.02-1.61), although the HR failed to attain statistical significance.

CONCLUSIONS

In an analysis of a nationwide pathology database in Sweden, we found the absolute risk of small bowel adenocarcinoma is low in individuals with CD. However, risks of small bowel adenocarcinoma and adenomas (but not carcinoids) are significantly increased in people with CD compared to people without this disease.

摘要

背景与目的

小肠癌的发病率正在上升。已有研究表明,乳糜泻(CD)与小肠癌之间存在关联,但针对大量队列的详细研究尚未进行。

方法

通过瑞典全国性病理学强化流行病学研究队列,我们从瑞典的 28 个病理科检索了 1965 年至 2017 年间所有被诊断为 CD 的患者的数据。CD 患者的定义为十二指肠或空肠绒毛萎缩(Marsh 3 期评分),与多达 5 名随机选择的普通人群对照个体相匹配。我们使用分层 Cox 回归计算小肠腺癌、腺瘤和类癌的危险比(HRs)。

结果

在中位随访 11 年期间,我们共确定了 48119 例 CD 患者(患者)和 239249 名对照个体。从 CD 诊断后的 1 年开始,29 例患者(0.06%)被诊断为小肠腺癌,而 45 名对照个体(0.02%)被诊断为小肠腺癌,7 例患者被诊断为类癌,而 31 名对照个体被诊断为类癌,48 例患者被诊断为腺瘤,而 50 名对照个体被诊断为腺瘤。相应的 HR 为小肠腺癌 3.05(95%置信区间 [CI],1.86-4.99)、类癌 0.59(95% CI,0.16-2.10)和腺瘤 5.73(95% CI,3.70-8.88)。HR 独立于性别和年龄。总体而言,在接受 10 年随访的每 2944 例 CD 患者中,会额外出现 1 例小肠腺癌。未来小肠腺癌的黏膜愈合风险呈负相关(HR,0.18;95%CI,0.02-1.61),尽管 HR 未达到统计学意义。

结论

在对瑞典全国性病理数据库的分析中,我们发现 CD 患者小肠腺癌的绝对风险较低。然而,与无该疾病的人群相比,CD 患者患小肠腺癌和腺瘤(但不是类癌)的风险显著增加。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验